Bellevue Asset Management’s AstraZeneca AZN Stock Holding History

Bellevue Asset Management’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-50	Closed	-$17.6K	–	383
2025 Q4	$17.6K	Hold	50	–	–	0.01%	246
2025 Q3	$14.9K	Hold	50	–	–	0.01%	258
2025 Q2	$14K	Hold	50	–	–	0.01%	262
2025 Q1	$14.7K	Hold	50	–	–	0.01%	252
2024 Q4	$13K	Hold	50	–	–	0.01%	266
2024 Q3	$15.6K	Hold	50	–	–	0.01%	252
2024 Q2	$15.6K	Hold	50	–	–	0.01%	242
2024 Q1	$13.7K	Hold	50	–	–	0.01%	244
2023 Q4	$13.4K	Hold	50	–	–	0.01%	249
2023 Q3	$13.5K	Hold	50	–	–	0.01%	242
2023 Q2	$14.4K	Hold	50	–	–	0.01%	244
2023 Q1	$14K	Hold	50	–	–	0.01%	250
2022 Q4	$13.6K	Hold	50	–	–	0.01%	255
2022 Q3	$11K	Hold	50	–	–	0.01%	271
2022 Q2	$13K	Hold	50	–	–	0.01%	271
2022 Q1	$13K	Hold	50	–	–	0.01%	295
2021 Q4	$12K	Hold	50	–	–	0.01%	312
2021 Q3	$12K	Hold	50	–	–	0.01%	319
2021 Q2	$12K	Hold	50	–	–	0.01%	320
2021 Q1	$10K	Hold	50	–	–	0.01%	352
2020 Q4	$11K	Hold	50	–	–	0.01%	338
2020 Q3	$11K	Buy	+50	New	+$5.56K	0.01%	316

Other funds holding AZN

Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Vanguard Asset Management London, Ec4n 8af $148B AUM

Bellevue Asset Management's AZN Position: Q1 2026 in Review

Bellevue Asset Management sold out of AstraZeneca (AZN) in Q1 2026, closing a stake of 50 shares — an estimated $17.6K sold.

Bellevue Asset Management first reported a position in AZN in Q3 2020 and held it in 22 quarters. The position peaked at $17.6K in Q4 2025. 1,383 funds tracked by Wall St. Rank hold AZN as of Q1 2026.

Bellevue Asset Management reported no remaining AstraZeneca position as of Q1 2026 after selling out during the quarter.
Bellevue Asset Management sold 50 AstraZeneca shares in Q1 2026, an estimated $17.6K.
Bellevue Asset Management first reported a position in AstraZeneca in Q3 2020 and held it in 22 quarters.
Bellevue Asset Management's AstraZeneca position peaked at $17.6K in Q4 2025.
1,383 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2026.

Based on Bellevue Asset Management's 13F filing for Q1 2026, filed 24 Apr 2026.